In addition, previous findings suggest that activation of the Keap1-Nrf2 signaling pathway provokes anti-obesity effects, which may be an additional benefit in the clinical use of this pathway [103]. This evidence concerns the gene NFE2L2 and obesity due to melanocortin 4 receptor deficiency.